featured
Sunitinib for Metastatic Progressive Phaeochromocytomas and Paragangliomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
Lancet 2024 Mar 16;403(10431)1061-1070, E Baudin, B Goichot, A Berruti, J Hadoux, S Moalla, S Laboureau, S Nölting, C de la Fouchardière, T Kienitz, T Deutschbein, S Zovato, L Amar, M Haissaguerre, H Timmers, P Niccoli, A Faggiano, M Angokai, L Lamartina, F Luca, D Cosentini, S Hahner, F Beuschlein, M Attard, M Texier, M FassnachtFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.